MaxCyte, Inc. Signing of Strategic Platform License (0021B)
September 28 2022 - 8:05AM
UK Regulatory
TIDMMXCT TIDMTTM
RNS Number : 0021B
MaxCyte, Inc.
28 September 2022
MaxCyte Signs Strategic Platform License with Vertex
Pharmaceuticals
to Advance CRISPR/Cas9-based Gene-editing Program
Vertex Pharmaceuticals will continue to use MaxCyte's Flow
Electroporation (R) technology and ExPERT(TM) platform to support
gene-edited cell therapy exa-cel, formerly known as CTX001(TM) for
hemoglobinopathies
ROCKVILLE , MD, September 28, 2022 -MaxCyte, Inc., (Nasdaq:
MXCT; LSE: MXCT), a leading commercial cell-engineering company
focused on providing enabling platform technologies to advance
innovative cell-based research as well as next-generation cell
therapeutic discovery, development and commercialization, today
announces the signing of a strategic platform license (SPL) with
Vertex Pharmaceuticals Incorporated, a global biotechnology company
that invests in scientific innovation to create transformative
medicines for people with serious diseases.
Under the terms of the agreement, Vertex obtains non-exclusive
clinical and commercial rights to use MaxCyte's Flow
Electroporation(R) technology and ExPERT(TM) platform in the
development of its CRISPR/Cas9-based gene-edited therapy (exa-cel,
formerly known as CTX001(TM)), which entitles MaxCyte to receive
platform licensing fees and program related revenue.
Exa-cel is an investigational ex vivo CRISPR gene-edited cell
therapy under evaluation for patients suffering from
transfusion-dependent beta thalassemia (TDT) or sickle cell disease
(SCD) characterized by recurrent vaso-occlusive crises.
The same MaxC yte technology was used in the development of
exa-cel under an agreement between MaxCyte and CRISPR
Therapeutics.
About MaxCyte
MaxCyte is a leading commercial cell-engineering company focused
on providing enabling platform technologies to advance innovative
cell-based research as well as next-generation cell therapeutic
discovery, development and commercialization. Over the past 20
years, we have developed and commercialized our proprietary Flow
Electroporation(R) platform, which facilitates complex engineering
of a wide variety of cells. Our ExPERT(TM) platform, which is based
on our Flow Electroporation technology, has been designed to
support the rapidly expanding cell therapy market and can be
utilized across the continuum of the high-growth cell therapy
sector, from discovery and development through commercialization of
next-generation, cell-based medicines. The ExPERT family of
products includes: four instruments, the ATx(TM), STx(TM)
GTx(TM)and VLx(TM); a portfolio of proprietary related processing
assemblies or disposables; and software protocols, all supported by
a robust worldwide intellectual property portfolio.
About Vertex Pharmaceuticals
Vertex is a global biotechnology company that invests in
scientific innovation to create transformative medicines for people
with serious diseases. The company has multiple approved medicines
that treat the underlying cause of cystic fibrosis (CF) - a rare,
life-threatening genetic disease - and has several ongoing clinical
and research programs in CF. Beyond CF, Vertex has a robust
pipeline of investigational small molecule medicines in other
serious diseases where it has deep insight into causal human
biology, including pain, alpha-1 antitrypsin deficiency and
APOL1-mediated kidney disease. In addition, Vertex has a rapidly
expanding pipeline of cell and genetic therapies for diseases such
as sickle cell disease, beta thalassemia, Duchenne muscular
dystrophy and type 1 diabetes mellitus.
Founded in 1989 in Cambridge, Mass., Vertex's global
headquarters is now located in Boston's Innovation District and its
international headquarters is in London. Additionally, the company
has research and development sites and commercial offices in North
America, Europe, Australia and Latin America. Vertex is
consistently recognized as one of the industry's top places to
work, including 12 consecutive years on Science magazine's Top
Employers list, one of the 2021 Seramount (formerly Working Mother
Media) 100 Best Companies, and a best place to work for LGBTQ
equality by the Human Rights Campaign.
MaxCyte Contacts:
US IR Adviser
Gilmartin Group +1 415-937-5400
David Deuchler, CFA ir@maxcyte.com
US Media Relations
Valerie Enes +1 408-497-8568
Seismic valerie@teamseismic.com
Nominated Adviser and Joint Corporate
Broker
Panmure Gordon
Emma Earl / Freddy Crossley
Corporate Broking
Rupert Dearden +44 (0)20 7886 2500
UK IR Adviser
Consilium Strategic Communications +44 (0)203 709 5700
Mary-Jane Elliott maxcyte@consilium-comms.com
Chris Welsh
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCLPMLTMTTTMTT
(END) Dow Jones Newswires
September 28, 2022 08:05 ET (12:05 GMT)
Maxcyte (LSE:MXCT)
Historical Stock Chart
From Jun 2024 to Jul 2024
Maxcyte (LSE:MXCT)
Historical Stock Chart
From Jul 2023 to Jul 2024